viralic
Forumer storico
per le borse propendo più per il gatto morto !!.....siamo ben lontani d aver risolto i problemi in primis quello della guerra petrolifera tra OPEC E RUSSIA.
NicOx.... in attesa di.....
- Creatore Discussione DickSIM
- Data di Inizio
per le borse propendo più per il gatto morto !!.....siamo ben lontani d aver risolto i problemi in primis quello della guerra petrolifera tra OPEC E RUSSIA.
PIZZODIGINO
Pacifico
quello della Nicox è stato il rimbalzo del topo morto.
elcucador
Forumer storico
il problema non sono solo la situazione esterna a nicox (cie' la situazione dei mercati),ma purtroppo,se ne aggiungono altri intrinsechi,per non dire del fatto che a suo tempo e' stata troppo sopravalutato questo titolo e ora vchiaramente il mercato se ne e' reso conto e non lo premia sulle riprese,ma rimane solo la piccola speculazione ad operare quasi sempre al ribasso e allo sfruttamento dei successivi rialzi ben pilotati.
e poi questa situazione pesera' almeno per tutto l'anno sui mercati e quindi nicox gia' e' incastrata da per se (parlo in termini di liquidita') e quindi sara' molto difficile finanziarsi in questa situazione visto ceh sara0 difficile fare un adc a prezzi piu' elevati degli attuali e se aggiungiamo che ci potrebbe essere (ma non ne sono sicuro) una manovra dei fondi per affossare il titolo e prendere il ceo per il collo allora e' davvero la fine del titolo e del ceo, e di questo sarei contento sarei contento anche se lui,purtroppo,cadra' in piedi mentre gli azionisti verrano macellati senza pieta'.
certo non sara' ben ricordato dagli azionisti ma e' solo una magra consolazione,purtroppo.
elcucador
Forumer storico
Penny pour la fin de l'année
Vista37
10 mars 2020•15:57
sans aucun doute quoi qu'en dise M938 depuis 5 ans
Aucune raison pour un chnagement de cap
Rien en portefeuille en dehors des ventes arrivé a maturité zet qui n'interesse personne
devellopement couteux pour produire rien de formidable
parole sacrosante,purtroppo e' la verita'.
caro pizzo questi titoli sono solo una trappola assoluta,ormai l'ho capito da un po',anche se un po' troppo tartdi.
sinceramente ora come ora si creeranno condizioni ottimali magari epr rientrare in borsa ma allora se uno ha ancora la voglia meglio puntare su titoli solidi come ENEL o Poste Italiane che su queste merdacce buone solo per far vivere da nababbi ceo,management e chi ci lavora e tutto il contorno di squali e squaletti vari e fondi banditeschi e case di investimento vari che sparano target solo per fare i comodacci loro,andrebbero tutti banditi dai mercati e chiusi in galera per quello che hanno fatto e continiano a fare e il mio discorso e' in senso generale.
caro pizzo purtroppo la realta' e' questa e credo che anche tu hai cominciato a capire.
Vista37
10 mars 2020•15:57
sans aucun doute quoi qu'en dise M938 depuis 5 ans
Aucune raison pour un chnagement de cap
Rien en portefeuille en dehors des ventes arrivé a maturité zet qui n'interesse personne
devellopement couteux pour produire rien de formidable
parole sacrosante,purtroppo e' la verita'.
caro pizzo questi titoli sono solo una trappola assoluta,ormai l'ho capito da un po',anche se un po' troppo tartdi.
sinceramente ora come ora si creeranno condizioni ottimali magari epr rientrare in borsa ma allora se uno ha ancora la voglia meglio puntare su titoli solidi come ENEL o Poste Italiane che su queste merdacce buone solo per far vivere da nababbi ceo,management e chi ci lavora e tutto il contorno di squali e squaletti vari e fondi banditeschi e case di investimento vari che sparano target solo per fare i comodacci loro,andrebbero tutti banditi dai mercati e chiusi in galera per quello che hanno fatto e continiano a fare e il mio discorso e' in senso generale.
caro pizzo purtroppo la realta' e' questa e credo che anche tu hai cominciato a capire.
elcucador
Forumer storico
se ci pensi bene val e0,64 considerando il raggruppamento a suo tempo di 1 a 5.
in pratica si sta avvicinando a zero,in usa e' una penny stock,e un titolo che scende cosi' in basso poi difficilmente ha grosse potenzialita' di rialzo.
e tutto questo nonostante le news "positive" arrivate.
comunque se ti va fai operazioni di acquisto e vendita sui rialzi chiaramente pilotati che ci saranno in futuro,su questo titolo e' l'unica strategia perche' essere long e' da perdenti,non e' un titolo interessante,non ci sono i motivi dopo il semiflop del vyzulta e penso che l'ncx 470 ricalchera' la stessa strada.
Ultima modifica:
PIZZODIGINO
Pacifico
caro Guly, la cosa che ho capito è che su Nicox si deve solo speculare e non investire.
è contro il mio modo normale di operare, ma mi sono adeguato.
è contro il mio modo normale di operare, ma mi sono adeguato.
viralic
Forumer storico
Press Release
Nicox to Receive €15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial from Ocumension Therapeutics under Amended Agreement
Nicox to Receive €15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial from Ocumension Therapeutics under Amended Agreement
- Ocumension will pay Nicox €15M
- Ocumension will additionally fund half of the costs of a joint U.S.-Chinese Phase 3 clinical trial on NCX 470, expected to begin in H2 2020, after the start of the Mont Blanc Phase 3 clinical trial
- Accelerates the NCX 470 development plans and New Drug Application (NDA) submissions in the U.S. and China
- Ocumension rights to NCX 470 are extended to Korea and South East Asian markets
viralic
Forumer storico
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its December 2018 licence agreement with Ocumension Therapeutics, which originally granted Ocumension exclusive rights to develop and commercialize NCX 470 for glaucoma in the Chinese market. Under the amended agreement, Ocumension will immediately pay Nicox €15 million (in place of the milestones in the original agreement), will gain additional rights to NCX 470 for Korea and South East Asia and will pay 50% of the costs of the second glaucoma Phase 3 clinical trial of NCX 470 (‘Denali’). The two companies will jointly manage the Denali trial in the U.S. and China.
NCX 470, a novel second generation nitric oxide (NO)-donating bimatoprost analog for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, is Nicox’s lead clinical development program. In the multicenter, Phase 2 clinical trial (‘Dolomites’) conducted in the U.S., NCX 470 demonstrated both statistical non-inferiority and superiority to latanoprost, the U.S. market leader in prostaglandin analog prescriptions.
“We believe conducting the Denali Phase 3 trial together will allow both companies to more effectively achieve the development goals for NCX 470,” said Gavin Spencer, Chief Business Officer of Nicox. “Bringing forward the Ocumension milestone payments in this way is a major step in the financing of the U.S. and Chinese NCX 470 programs allowing us to initiate both Phase 3 clinical trials this year and accelerating the NDA submission of NCX 470 in the U.S. and Chinese markets.”
Ocumension is funded by top-tier venture capital investors including 6 Dimensions Capital and other distinguished investors. Ocumension recruited highly qualified management and development teams with significant international experience gained in companies including Santen, Alcon and Novartis. The Ocumension team has conducted ophthalmology clinical studies in China previously and has the
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its December 2018 licence agreement with Ocumension Therapeutics, which originally granted Ocumension exclusive rights to develop and commercialize NCX 470 for glaucoma in the Chinese market. Under the amended agreement, Ocumension will immediately pay Nicox €15 million (in place of the milestones in the original agreement), will gain additional rights to NCX 470 for Korea and South East Asia and will pay 50% of the costs of the second glaucoma Phase 3 clinical trial of NCX 470 (‘Denali’). The two companies will jointly manage the Denali trial in the U.S. and China.
NCX 470, a novel second generation nitric oxide (NO)-donating bimatoprost analog for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, is Nicox’s lead clinical development program. In the multicenter, Phase 2 clinical trial (‘Dolomites’) conducted in the U.S., NCX 470 demonstrated both statistical non-inferiority and superiority to latanoprost, the U.S. market leader in prostaglandin analog prescriptions.
“We believe conducting the Denali Phase 3 trial together will allow both companies to more effectively achieve the development goals for NCX 470,” said Gavin Spencer, Chief Business Officer of Nicox. “Bringing forward the Ocumension milestone payments in this way is a major step in the financing of the U.S. and Chinese NCX 470 programs allowing us to initiate both Phase 3 clinical trials this year and accelerating the NDA submission of NCX 470 in the U.S. and Chinese markets.”
Ocumension is funded by top-tier venture capital investors including 6 Dimensions Capital and other distinguished investors. Ocumension recruited highly qualified management and development teams with significant international experience gained in companies including Santen, Alcon and Novartis. The Ocumension team has conducted ophthalmology clinical studies in China previously and has the
viralic
Forumer storico
March 11, 2020 – release at 7:35 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its March 2019 license agreement with Ocumension Therapeutics granting Ocumension exclusive rights to develop and commercialize ZERVIATETM (cetirizine ophthalmic solution), 0.24% for the treatment of allergic conjunctivitis in the Chinese market. Under the amended agreement, Ocumension now also has exclusive rights of ZERVIATE in the majority of South East Asian Region.
“In addition to the expansion of our deal with Ocumension on NCX 470, also announced today, we have decided to broaden our relationship on ZERVIATE, adding this important emerging area of Asian markets to the original license,” said Gavin Spencer, Chief Business Officer of Nicox. “Ocumension has commenced construction of a new manufacturing site in China which will ultimately be able to manufacture ZERVIATE and therefore be well-placed to supply these additional territories.”
“The development teams at Ocumension and Nicox have been working together to prepare the Chinese IND. We expect to file this shortly and be in a position to start a Phase 3 clinical trial for approval in China by Q4 2020,” said Ye Liu, Chief Executive Officer of Ocumension.
Amendment Agreement Terms
Ocumension has exclusive rights in the original and expanded territories to develop and commercialize ZERVIATE for the treatment of allergic conjunctivitis. Other terms of the original agreement remain unchanged and Nicox may potentially receive development and sales milestones of up €17 million together with tiered royalties of between 5% and 9% on sales of ZERVIATE.
About Nicox
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its March 2019 license agreement with Ocumension Therapeutics granting Ocumension exclusive rights to develop and commercialize ZERVIATETM (cetirizine ophthalmic solution), 0.24% for the treatment of allergic conjunctivitis in the Chinese market. Under the amended agreement, Ocumension now also has exclusive rights of ZERVIATE in the majority of South East Asian Region.
“In addition to the expansion of our deal with Ocumension on NCX 470, also announced today, we have decided to broaden our relationship on ZERVIATE, adding this important emerging area of Asian markets to the original license,” said Gavin Spencer, Chief Business Officer of Nicox. “Ocumension has commenced construction of a new manufacturing site in China which will ultimately be able to manufacture ZERVIATE and therefore be well-placed to supply these additional territories.”
“The development teams at Ocumension and Nicox have been working together to prepare the Chinese IND. We expect to file this shortly and be in a position to start a Phase 3 clinical trial for approval in China by Q4 2020,” said Ye Liu, Chief Executive Officer of Ocumension.
Amendment Agreement Terms
Ocumension has exclusive rights in the original and expanded territories to develop and commercialize ZERVIATE for the treatment of allergic conjunctivitis. Other terms of the original agreement remain unchanged and Nicox may potentially receive development and sales milestones of up €17 million together with tiered royalties of between 5% and 9% on sales of ZERVIATE.
About Nicox
PIZZODIGINO
Pacifico
onestamente mi aspettavo di più.
